# A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

> **NCT05911217** · PHASE1 · RECRUITING · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CT041 autologous CAR T-cell injection

## Key facts

- **NCT ID:** NCT05911217
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911217, "A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05911217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*